WG
CRNX

Winton Group’s Crinetics Pharmaceuticals CRNX Stock Holding History

Winton Group’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-28,384
Closed -$1.32M – 1163
2025
Q4 		$1.32M Sell
28,384
-39,816
-58% -$1.77M 0.05% 385
2025
Q3 		$2.84M Buy
+68,200
New +$2.18M 0.11% 237

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.06B AUM 215.32% 1-Year Est. Return

Winton Group's CRNX Position: Q1 2026 in Review

Winton Group sold out of Crinetics Pharmaceuticals (CRNX) in Q1 2026, closing a stake of 28,384 shares — an estimated $1.32M sold.

Winton Group first reported a position in CRNX in Q3 2025 and held it in 2 quarters. The position peaked at $2.84M in Q3 2025. 243 funds tracked by Wall St. Rank hold CRNX as of Q1 2026.

  • Winton Group reported no remaining Crinetics Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Winton Group sold 28,384 Crinetics Pharmaceuticals shares in Q1 2026, an estimated $1.32M.
  • Winton Group first reported a position in Crinetics Pharmaceuticals in Q3 2025 and held it in 2 quarters.
  • Winton Group's Crinetics Pharmaceuticals position peaked at $2.84M in Q3 2025.
  • 243 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q1 2026.

Based on Winton Group's 13F filing for Q1 2026, filed 12 May 2026.